FDMT4D Molecular Therapeutics, Inc.
Price
+53%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, the market undecided.
Charts
As reported to the SEC, without any scoring.
4D Molecular Therapeutics, Inc. (FDMT) reported revenue of $3.8M in Q2 2026 (quarter ended Jun 30, 2026), up 25107% from the same quarter a year earlier. That came with net loss of $73M. For the full year FY2025, revenue was $85M (+230195% year on year) and net income −$140M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 28, 2026On September 28, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (“DME”)Other event · Form 8-K
- Aug 13, 20264DMT Reports Second Quarter 2026 Financial Results, Operational Highlights.Earnings release · press release
- Jun 29, 2026On June 24, 2026 (the “Closing Date”), 4D Molecular Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Hercules Capital, Inc. (“Hercules”), providing for term loans in an aggregate principal amount of up to $200.0 million, subject to the terms and conditions set forth …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.